Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
Fu W, Chen Y, Wang K, Hettinghouse A, Hu W, Wang J, Lei Z, Chen Z, Stapleford K, Liu C. Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. Protein & Cell 2020, 12: 586-591. PMID: 33210243, PMCID: PMC7673315, DOI: 10.1007/s13238-020-00803-w.Peer-Reviewed Original ResearchAngiotensin-Converting Enzyme 2COVID-19Drug RepositioningEnzyme-Linked Immunosorbent AssayHumansPharmaceutical PreparationsSARS-CoV-2